

# **CARDIOVASCULAR COMPLICATIONS SECONDARY TO CHEMOTHERAPY IN AGGRESSIVE NONHODGKIN LIMPHOMAS.**

***Zoe Cojan<sup>1</sup>, Monica Pescaru<sup>2</sup>, Diana Ursescu<sup>2</sup>,  
Ruxandra Dabici<sup>2</sup>, Ovidiu Potre<sup>1</sup>, Cristina Sorica<sup>1</sup>,  
Raluca Cornean<sup>2</sup>, Ema Budai<sup>2</sup>, Ana Maria Focht<sup>2</sup>,  
Maria Iordache<sup>1</sup>, Hortensia Ionita<sup>1</sup>***

<sup>1</sup> University of Medicine and Pharmacy "Victor Babes" Timisoara, Romania

<sup>2</sup> Emergency Municipal Hospital , Clinic of Hematologie, Timisoara, Romania.

## **INTRODUCTION**

The non-Hodgkin lymphoma is a malignant cell proliferation. The starting point is affecting lymphoid tissue B cells and T In aggressive NHL, most often encountered chemotherapy, according to protocol, is multi-agent CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in combination with monoclonal antibodies (rituximab).

## **PURPOSE**

The purpose of the study is tracking secondary cardiovascular complications that arise polichimiotherapy type CHOP and R-CHOP respectively.

## **METHODS**

We conducted a retrospective study on a group of 47 patients from Timisoara Hematology Clinic, with non-Hodgkin lymphoma highly malignitate, during 01.2010-02.2015. The diagnosis was based on clinical features, histopathological, immunohistochemical exams , bone marrow aspirate, cytogenetics and radiological investigations. (radiography, CT scan).

## **RESULTS**

Of the 47 patients, age incidence is highest between 40-60 years 48.94%, followed by 31.91% between 60-80 years and 19.15% between 20-40% are women ani.57.45 , 42.55% men; 44.68% alive, 55.32% died. Of the 47 patients, cardiovascular complications that arise after treatment, 29.79% had hypertension, ischemic heart disease 19.15%, 6.38% heart failure, 4.25% thrombosis, arrhythmias type atrial fibrillation, right bundle branch block. and 2% valvular type mitral regurgitation and aortic

## **CONCLUSION**

Cardiovascular complications that occurred after treatment according to the protocol CHOP and R-CHOP that are in the forefront hypertension, ischemic cardiomyopathy and heart failure.